Loading...
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitor...
Saved in:
| Published in: | J Pathol Transl Med |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
The Korean Society of Pathologists and the Korean Society for Cytopathology
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6639705/ https://ncbi.nlm.nih.gov/pubmed/31042863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4132/jptm.2019.04.24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|